Key result
PARP inhibitors in ovarian cancer show a ~5% thromboembolic event rate, predicted by BRCA2 mutations.
Why the study?
The study was conducted to determine the real-world incidence and predictive factors for venous and arterial thromboembolic events in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors.
Cohort (n=329)
Yes
In patients with ovarian cancer treated with PARP inhibitors, the incidence of VTE/AT is 4.9%, with BRCA2 mutations acting as a potential predictor of thrombosis.
May warrant heightened thrombosis surveillance during PARP inhibitor therapy; BRCA2 association is hypothesis-generating and needs prospective validation.
PURPOSE: To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP). METHODS/PATIENTS: A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT. Secondary outcomes included predictive factors for thrombosis and the impact of thrombosis on overall survival (OS). Data were analyzed using logistic regression and Kaplan-Meier survival analysis. RESULTS: The incidence of VTE/AT was 4.9% (16/329). BRCA2 mutations were significantly more prevalent among patients who developed VTE/AT (56.3% vs. 19.2%; p < 0.001). Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). No statistically significant differences were observed in the median OS between patients who experienced VTE/ATE (63 months) and those who did not (47 months), with a p value of 0.876. CONCLUSIONS: BRCA2 mutations could be a significant predictor for VTE/AT among ovarian cancer patients treated with iPARP. Concomitant treatment with bevacizumab may offer protection against thrombotic events, although a concomitant bias cannot be ruled out. These findings may be of interest when designing future clinical trials in the field of thromboprophylaxis.
No takes yet. Share an insight, caveat, or question.
Sánchez-Cánovas et al. (2025) conducted a cohort in Ovarian cancer (n=329). PARP inhibitors was evaluated on Incidence of venous and arterial thromboembolic events (VTE/AT). In patients with ovarian cancer treated with PARP inhibitors, the overall incidence of venous and arterial thromboembolic events was 4.9%, with BRCA2 mutations acting as a significant predictor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: